Howard D. Palefsky
Victoria Capital Management, Inc.
Member

Mr. Palefsky has extensive experience as an Entrepreneur, CEO, Board Chair, Director and Investor in the life sciences, medical device, healthcare and health and wellness industries. Businesses in which Mr. Palefsky played a significant role have achieved in excess of $3 billion of value creation; more than 40 product launches; 20 company formations, and numerous financings, IPOs and M & A transactions.   
He has deep experience in general management, marketing, finance, manufacturing, R & D, regulatory and quality affairs, reimbursement and healthcare policy; and he has managed operations and investments in the U.S., Europe, Japan, Australia and emerging markets. Mr. Palefsky has extensive experience in managing the intersection of the consumer and healthcare provider to produce useful products and services and valuable companies.

Professional History
Mr. Palefsky is an independent investor in and a director and advisor to healthcare companies and operates through a family investment company, Victoria Capital Management, Inc.  He was a Managing Director at Montreux Equity Partners (www.mepvc.com) from 2002 - 2015. He was a Venture Partner at Montreux from 1999--2002, as well as Chairman and CEO of portfolio company, NeurogesX. 

From 1997-1999, Mr. Palefsky was an advisor to Collagen Corporation. He was also a Director, and Executive Chairman of a number of public and private companies.

From 1978 to 1997, Mr. Palefsky was the Chairman, President, Chief Executive Officer, and Director of Collagen Corporation, a pioneer in the aesthetic medicine field. He joined Collagen as CEO when it was a pre-revenue, venture-funded start-up with nine employees and led it through numerous financings; product approvals and launches in the US, Europe and Japan; profitability, and its Initial Public Offering. Mr. Palefsky managed the creation of Collagen’s spin-off companies Celtrix Laboratories. Target Therapeutics and Cohesion (sold to Angiotech), as well as its investment in Pharming N.V.  Collagen was sold to Inamed (now Allergan) in 1999.

Earlier, Mr. Palefsky was Vice President of Marketing at the ALZA Pharmaceuticals division of ALZA Corp. (now Johnson & Johnson) from 1973 - 1978 and a Marketing Manager at American Home Products (now Pfizer) from 1971 - 1973.

Representative Accomplishments
At Montreux Mr. Palefsky was a senior member of the team that raised approximately $500 million in funds from Limited Partners. In addition he was a senior member of the investment team that purchased interests in more than 35 companies, including: Peninsula Pharmaceuticals (sold to Johnson & Johnson), Cerexa Phramaceuticals (to Forest Laboratories), Novacardia (to Merck), Orexigen (NASDAQ: OREX), SkinMedica (to Allergan), Asthmatx (to Boston Scientific), Renal Care Partners (to ASA),  MAKO Surgical (to Stryker), Pivot (to Stryker), Glaukos (NASDAQ:GKOS) and Mind Body (NASDAQ;MB).

Most recently, Mr. Palefsky was a Montreux board member at Colorescience, Pure Life Renal, GC Aesthetics, moksha8, Avantis Medical Systems, Pulmonx, NovoStent and Percutaneous Systems. Previously, he was a board member representing Montreux at Enterics Medical (sold to Boston Scientific), ProDuct Health (to Hologic), Coalescent Surgical (to Medtronic) and Questcor Pharmaceutcals (to Mallinckrodt).  

As CEO of Collagen, Mr. Palefsky executed Collagen's investment in Target Therapeutics and was instrumental in Target’s founding and its ultimate sale to Boston Scientific for $1.2 billion (netting Collagen $200 million on a $7 million investment). As a Board member of Target he played a central role in conceiving and executing Target’s spin-offs, including   Conceptus (to Bayer) and ProGraft (to W.L. Gore). 

Mr. Palefsky has also been an active Private Investor / Director in life sciences and healthcare companies, including: Laserscope (sold to American Medical Systems), Resound Corp (to GN Danavox), Novacept Corp. (to Hologic), Oclassen Pharmaceuticals (to Watson/Allergan), Calgene (to Monsanto), Sequana Therapeutics (to Celera/Quest), Conceptus (to Bayer), Innovasive Devices (to J&J) InterVentional Technologies (to Boston Scientific) and Berkeley Heart Laboratories (to Celera/Quest). 

Personal Data and Philanthropic Interests
Mr. Palefsky received his M.B.A. from the Stanford University Graduate School of Business in 1971 and his B.S (mathematics) from the City College of the City University of New York in 1967.  He also served as an officer in the United States Public Health Service from 1967 to 1969.

Mr. Palefsky currently serves as a Board Member and Treasurer of the 21st Century Foundation of the City College of New York, and a member of the Boards of the Atlanta Symphony Orchestra and the Atlanta History Center.   He is also a member of the World Presidents’ Organization (WPO) and The Chief Executives Organization (CEO).  

Mr. Palefsky is married to the former Victoria Baxter and they reside in Atlanta, Georgia. They have three grown children and are active participants in, and supporters of, the arts and academic communities in Atlanta, New York City, Palo Alto, and Santa Fe.